OncoMatch/Clinical Trials/NCT07180927
DLL3 CAR-T Therapy Targeting Brain Tumors
Is NCT07180927 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies 4SCAR DLL3 T cells for glioblastoma of cerebellum.
Treatment: 4SCAR DLL3 T cells — The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic pontine or midline gliomas (DIPG or DMG). Another goal of the study is to learn more about the function of the anti-DLL3 CAR-T cells and their persistency in patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Demographics
Prior therapy
Must have received: standard care of medication, such as gross total resection with concurrent radio-chemotherapy (~54 - 60 Gy, TMZ) (temozolomide)
Patients have received standard care of medication, such as gross total resection with concurrent radio-chemotherapy (~54 - 60 Gy, TMZ)
Cannot have received: gliadel implantation
Exception: within 4 weeks before study start
a prior history of gliadel implantation 4 weeks before this study start
Cannot have received: antibody based therapies
Exception: currently receiving
currently receiving antibody based therapies
Lab requirements
Blood counts
absolute neutrophile count ≥ 1500/mm^3; hemoglobin > 10 g/dL; platelets > 100000 /mm^3; peripheral blood absolute lymphocyte count must be above 0.8×10^9/L
Kidney function
creatinine < 1.5×ULN
Liver function
Bilirubin < 1.5×ULN; ALT or AST < 2.5×ULN
Cardiac function
satisfactory heart functions
satisfactory bone marrow, liver and kidney functions as defined by the following: absolute neutrophile count ≥ 1500/mm^3; hemoglobin > 10 g/dL; platelets > 100000 /mm^3; Bilirubin < 1.5×ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5×ULN; creatinine < 1.5×ULN; peripheral blood absolute lymphocyte count must be above 0.8×10^9/L; satisfactory heart functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07180927 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gliadel implantation, antibody based therapies disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages